Sacubitril/valsartan can improve the cardiac function in heart failure patients with a history of cancer: An observational study
- Published on 06/10/2024
- Reading time: 7 min.
Chen, Zhulua; Zhang, Chuan Phda; Zhu, Yuxi Phdb; Gao, Diansa Phda; Mao, Min Phda; Zuo, Zhong Phda,*
Abstract
Sacubitril/Valsartan, the combination of angiotensin receptor inhibitor and neprilysin inhibitor, is now becoming the class 1 recommendation for HFrEF. Some studies have shown the positive effect of Sacubitril/Valsartan on HFrEF cancer patients, while there is devoid of evidence about the effect of this drug in aged cancer patients with HFmrEF and HFpEF. By searching the patients with a diagnosis of both...
To continue reading this article in Full-Text...
* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Cardiology
Receive our newsletter to stay up to date with the latest news in Cardiology
More articles
From peer-reviewed journals
in Cardiology